Skip to content

Study · Randomized controlled trial · n = 51 · 2015

4 results

The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.

Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R

The Journal of clinical endocrinology and metabolism31 Jul 2015Cited by 41 (Europe PMC)

PMID26230296 (opens in a new tab)DOI10.1210/jc.2015-2725 (opens in a new tab)PepBankPUB-26230296
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, liraglutide enhanced the insulin response to an oral glucose challenge compared with placebo at 12, 24, 36 and 48 weeks.

    In plain wordsIn adults with early type 2 diabetes, liraglutide raised the insulin response after a glucose drink more than placebo did.

    Peptide
    Liraglutide
    Outcome
    IncreasePostchallenge insulin response
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    As expected, compared with placebo, liraglutide induced a robust enhancement of the postchallenge insulin and C-peptide response at each of the 12-, 24-, 36-, and 48-week time points, with a concomitant reduction in glycemic excursion.
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the impact of chronic liraglutide therapy on glucagon regulation in early T2DM.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, liraglutide enhanced the C-peptide response to an oral glucose challenge compared with placebo at 12, 24, 36 and 48 weeks.

    In plain wordsIn adults with early type 2 diabetes, liraglutide raised the C-peptide response after a glucose drink more than placebo did.

    Peptide
    Liraglutide
    Outcome
    IncreasePostchallenge C-peptide response
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    As expected, compared with placebo, liraglutide induced a robust enhancement of the postchallenge insulin and C-peptide response at each of the 12-, 24-, 36-, and 48-week time points, with a concomitant reduction in glycemic excursion.
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the impact of chronic liraglutide therapy on glucagon regulation in early T2DM.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, liraglutide reduced the glycemic excursion after an oral glucose challenge compared with placebo.

    In plain wordsIn adults with early type 2 diabetes, liraglutide reduced the rise in blood sugar after a glucose drink compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic excursion after glucose challenge
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    As expected, compared with placebo, liraglutide induced a robust enhancement of the postchallenge insulin and C-peptide response at each of the 12-, 24-, 36-, and 48-week time points, with a concomitant reduction in glycemic excursion.
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the impact of chronic liraglutide therapy on glucagon regulation in early T2DM.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, baseline-adjusted glucagon response (iAUCglucagon) after an oral glucose challenge was higher with liraglutide than with placebo at 12, 36 and 48 weeks.

    In plain wordsIn adults with early type 2 diabetes, liraglutide raised the glucagon response after a glucose drink compared with placebo for 48 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreasePostchallenge glucagon response (iAUCglucagon)
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    iAUCglucagon
    170.2 pg/mL · 2 hours
    liraglutide, 12 weeks
    iAUCglucagon
    65.4 pg/mL · 2 hours
    placebo, 12 weeks
    iAUCglucagon
    162.2 pg/mL · 2 hours
    liraglutide, 36 weeks
    iAUCglucagon
    55.7 pg/mL · 2 hours
    placebo, 36 weeks
    iAUCglucagon
    155.5 pg/mL · 2 hours
    liraglutide, 48 weeks
    iAUCglucagon
    45.7 pg/mL · 2 hours
    placebo, 48 weeks

    Source sentences

    Summary
    Indeed, baseline-adjusted iAUCglucagon was significantly higher in the liraglutide group compared with placebo at 12 weeks (170.2 ± 34.9 vs 65.4 ± 36.4 pg/mL · 2 hours, P = .04), 36 weeks (162.2 ± 27.9 vs 55.7 ± 30.4 pg/mL · 2 hours, P = .01), and 48 weeks (155.5 ± 26.5 vs 45.7 ± 27.0 pg/mL · 2 hours, P = .006).
    1 context sentence
    Summary · context
    The purpose of this study was to evaluate the impact of chronic liraglutide therapy on glucagon regulation in early T2DM.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01270789

LIraglutide and Beta-cell RepAir (LIBRA) Study

Mount Sinai Hospital, Canadan = 63Jan 2011 to May 2014

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 12 Sept 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.